June 22, 2023 11:08 AM EDT
Deals
R&D

Aslan out­li­cens­es atopic der­mati­tis an­ti­body in $138.5M deal

Paul Schloesser

Associate Editor

Aslan Phar­ma­ceu­ti­cals grant­ed ex­clu­sive de­vel­op­ment and com­mer­cial­iza­tion rights in Japan for an IL-13 an­ti­body to a Japan­ese drug­mak­er in a deal worth up to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times